Latest News & Features
Big Pharma
On June 24, 2020, a seven-year long legal battle between two biotech companies finally concluded in the UK. 8 March 2021
Big Pharma
UK innovation hub CPI has received a further £5 million investment from the UK government to support the development of new mRNA vaccines to protect against new variants of COVID-19. 4 March 2021
Big Pharma
GlaxoSmithKline has avoided paying $57 million in damages after a US supreme court reversed a ruling that the pharmaceutical company should not have stopped issuing royalties on a lupus drug. 4 March 2021
Americas
The result of the sovereign immunity bid mirrored previous cases but we did learn something about the opinions of Justices on the issue, says Gary Frischling of Milbank. 4 March 2021
article
Join LSPN Connect for an in-depth two-part look at the Regeneron v Kymab case. On Thursday, March 4, we will be joined by some of the participants of the latest proceedings before the UK Supreme Court. 4 March 2021
Medtech
Thom Tillis, ranking member of the senate IP subcommittee, has urged US president Joe Biden to oppose ‘harmful’ proposals to waive rights related to COVID-19 vaccines currently in discussions at the World Trade Organisation. 2 March 2021
Big Pharma
Los Angeles company Puma Biotechnology and Beijing-based CANBridge Pharmaceuticals have cancelled a 2018 licensing deal which gave the latter exclusive rights to a breast cancer drug in China. 2 March 2021
Medtech
The Indian government has called upon members of the WTO to deliver on its proposal to waive IP obligations in order to deal more effectively with the COVID-19 pandemic. 2 March 2021
Biotechnology
Since the formalisation of the new Biologics Price Competition and Innovation Act (BPCIA) framework in 2014, there has been a wave of patent infringement litigation, leading to a trend of innovator-versus-biosimilar disputes. 2 March 2021
Biotechnology
The Biologics market has changed dramatically since the introduction of the Biologics Price Competition and Innovation Act in 2014 in the US. The act provides a pathway for similar biologics to make it to market safely, cost-effectively, and legally. 1 March 2021